$FTRE

Fortrea Holdings Inc. (FTRE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Accounting Officer Effective October 5, 2026, Fortrea Holdings Inc. (the “Company”) appointed Carrie R

Fortrea Holdings (FTRE) reinstated Jason Knoblauch as CFO, resolving prior legal restrictions. This reduces uncertainty around finance operations amid key operational themes. The company focuses on clinical trial outsourcing growth, cost programs, and customer engagement. FTRE reported losses of $85.2M on $2.68B revenue, with a P/S of 0.7x. Analysts project $3.0B revenue and $5.2M earnings by 2029, while cautious estimates suggest $2.9B revenue and $473.4M earnings.

Fortrea Holdings (FTRE) reinstated Jason Knoblauch as CFO in September 2026, resolving a legal dispute. The company granted inducement equity awards tied to performance, focusing on leadership stability and cost objectives. Analysts project $3.0B revenue and $5.2M earnings by 2029, with a 21% potential upside. Risks include pricing pressure and customer concentration.

Fortrea (FTRE) granted inducement equity awards to five new hires, including its CFO, Jason Knoblauch. Knoblauch received 106,755 PSUs and 144,434 RSUs, vesting over three years. Other employees received 157,500 RSUs. Awards follow Nasdaq Rule 5635(c)(4) and were approved by independent directors.

Former Fortrea (FTRE) officer Jill G. McConnell filed a Rule 144 notice to sell 1,071 shares, valued at $17,699.88, including shares to cover taxes from a vested equity award. She previously sold 4,892 shares for $88,975.21 and 1,051 shares for $17,705.57 in the prior three months. The shares were acquired through restricted stock vesting as compensation.

Fortrea Holdings Inc. named Jason Knoblauch as principal financial officer, effective September 9, 2026. David Smith, a board director, stepped down as interim CFO but remains on the board. Fortrea is a global CRO providing clinical development services.

Fortrea Holdings Inc. (FTRE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2026, the Board of Directors (the “Board”) of Fortrea Holdings, Inc. (the “Company”) reinstated Jason Knobl

SAIC (NASDAQ:SAIC) rose 5.5% after beating Q2 2026 estimates. Reddit (NYSE:RDDT) fell 3.4% following EU regulatory action. Fortrea (NASDAQ:FTRE) gained 3% on acquisition news. GitLab (NASDAQ:GTLB) surged 10.9% after strong Q2 2026 results. G-III (NASDAQ:GIII) dropped 9.2% due to revenue miss and weak guidance.

Limbach (LMB) rose 8.1% after acquiring 1901 Inc. for $63M. FuelCell Energy (FCEL) fell 16.9% on weak Q2 2026 results. Ollie's (OLLI) gained 4.2% on strong Q2 2026 earnings and raised its full-year outlook. Fortrea (FTRE) rose 3% after acquiring Worldwide Clinical Trials' Early Phase Services. G-III (GIII) dropped 9.2% on missed Q2 revenue and soft guidance.

Fortrea is acquiring Worldwide Clinical Trials’ Early Phase Services division for $45M, including clinical pharmacology units and bioanalytical labs. Sponsors with active studies face contract, operational, and regulatory challenges during the 90-day integration period, requiring immediate attention to agreements, bioanalytical method transfers, and staff continuity.